Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Solitary Pulmonary Nodule 1Rectal Neoplasms 1Pain, Postoperative 1Lymphedema 1Lung Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1Anatomic Stage IV Breast Cancer AJCC v8 1Anatomic Stage II Breast Cancer AJCC v8 1Adenocarcinoma of Lung 1

Interventions

trastuzumab biosimilar HLX02 2ribociclib 2pertuzumab 2Trastuzumab 2Taxes 2Specimen Handling 2Paclitaxel 2PF-05280014 2Ontruzant 2Ogivri 2Magnetic Resonance Spectroscopy 2Drug Therapy 2Docetaxel 22C4 antibody 2tucatinib 1exemestane 1durvalumab 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Mastectomy, Segmental 1Mastectomy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Fulvestrant 1Fluorodeoxyglucose F18 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anatomic Stage II Breast Cancer AJCC v8 × Mastectomy, Segmental × 90 days × Clear all
NCT04266249 2026-05-05

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
2,175 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡